Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IONIS-AGT-LRx (Evazarsen) in Uncontrolled Hypertension
NCT04714320Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
A Phase 2 trial of evazarsen in hypertension (HTN), sponsored by Ionis Pharmaceuticals. Started Apr 2021; status: completed.
02
Drugs
evazarsen
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04714320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04714320.